Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Chaganti, Sridhar  [Clear All Filters]
2024
Mahadeo KMichael, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicent. Lancet Oncol. 2024.
2023
Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, et al. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study. Adv Ther. 2023.
2021
Fox CP, Ali AS, McIlroy GW, Thust SCatherine, Martinez-Calle N, Jackson AE, Hopkins L, Thomas CM, Kassam S, Wright J, et al. A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Adv. 2021.
2020
McIlroy G, Barmayehvar B, Kamarajah SK, George L, Gondal AZ, Malladi R, Chaganti S. Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma. Eur J Haematol. 2020.
2013
Chandratheva A, Singh ARamlackhan, Sturman S, Chaganti S, Jacob S. FEVER AND CONFUSION IN A RETURNING SOLDIER. J Neurol Neurosurg Psychiatry. 2013;84(11):e2.